Contracts Finder

NHS London Branded Medicines - Tranche B - September 2023

NHS England

Awarded
goods
SME-friendly

This tender has closed

The submission deadline for this contract has passed. There may be more active goods tenders from NHS England, and hundreds more across the UK public sector.

Key details

Contracting authority
NHS England
nhs
Region
Runcorn
Delivery: United Kingdom
Sector
Healthcare & Medical
Contract value
£231,083,266ex VAT
Submissions closed
17 April 2023
Published
13 March 2023

Procurement

Contract period
1 September 2023 - 31 August 2025
2 years
Procedure type
Open procedure (above threshold)
CPV classifications
  • 33600000 Pharmaceutical products

What happened

NHS England awarded this contract to Thornton and Ross Ltd | Biogen | GlaxoSmithKline UK Limited | Accord-UK Ltd | Celltrion Healthcare United Kingdom Limited | Sandoz Ltd | Zentiva Pharma UK Ltd | Takeda UK Ltd | Orifarm UK | Merck Sharpe & Dohme (UK) Limited | Teva UK Limited | CST Pharma Limited | Roche Products Ltd | AstraZeneca | Kent Pharma Ltd | Pfizer Ltd | Mylan | Abbvie Ltd | Janssen-Cilag Ltd | Eli Lilly & Company Ltd | Ipsen | Organon Pharmaceuticals UK Ltd | Almirall | Sun Pharma UK Ltd | Aventis Pharma ltd t/a Sanofi | Gedeon Richter UK Ltd | Merck Serono Limited | Novartis Pharmaceuticals UK Ltd | Galapagos Biotech UK Ltd | Novo Nordisk | Typharm Ltd | Sobi (Swedish Orphan Biovitrum Ltd) | Gilead Sciences Limited | Neon Healthcare Ltd | Bayer Plc | UCB Pharma Ltd worth £231,083,000 on 14 Jul 2023. The contract runs until 31 Aug 2025.

Description

NHS London Branded Medicines - Tranche B - September 2023

Offer reference number: CM/PHR/22/5677

CM/PHR/22/5677/01 - NHS Framework for London Branded Medicines - Tranche B. Period of framework: 1 September 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/22/5677/02 - NHS Framework for London Branded Medicines - Annual Tranche. Period of framework: 1 September 2023 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Awarded suppliers (36)

Suppliers
  • Thornton and Ross Ltd
  • Biogen
  • GlaxoSmithKline UK Limited
  • Accord-UK Ltd
  • Celltrion Healthcare United Kingdom Limited
  • Sandoz Ltd
  • Zentiva Pharma UK Ltd
  • Takeda UK Ltd
  • Orifarm UK
  • Merck Sharpe & Dohme (UK) Limited
  • Teva UK Limited
  • CST Pharma Limited
  • Roche Products Ltd
  • AstraZeneca
  • Kent Pharma Ltd
  • Pfizer Ltd
  • Mylan
  • Abbvie Ltd
  • Janssen-Cilag Ltd
  • Eli Lilly & Company Ltd
  • Ipsen
  • Organon Pharmaceuticals UK Ltd
  • Almirall
  • Sun Pharma UK Ltd
  • Aventis Pharma ltd t/a Sanofi
  • Gedeon Richter UK Ltd
  • Merck Serono Limited
  • Novartis Pharmaceuticals UK Ltd
  • Galapagos Biotech UK Ltd
  • Novo Nordisk
  • Typharm Ltd
  • Sobi (Swedish Orphan Biovitrum Ltd)
  • Gilead Sciences Limited
  • Neon Healthcare Ltd
  • Bayer Plc
  • UCB Pharma Ltd
Award value
£231,083,000
Award date
14 July 2023

Contact

Address
2nd Floor Rutland House, Runcorn, WA7 2ES
Website
https://health-family.force.com/s/Welcome
Contact name
Katie Noonan
Email
[email protected]

Identifiers

Buyer reference
CF-1617100D0O000000rwimUAA
Notice ID
3cb166f4-d32d-4d24-ba5f-9127da489fc3-671149
OCID
ocds-b5fd17-1b053612-ac3a-4f54-94e9-20ce45ce8a49

Explore related tenders

Other tenders from NHS England

View all →
Secondary Care Medicines Data Pre-Market Engagement£6,750,000
Quality Assurance & Improvement of Structured Learning Placement (SLP) Modules£98,000
Targeted Prostate Cancer Screening Programme - MRI Reporting Service
Targeted Prostate Cancer Screening Programme – PSA Laboratory Processing Service
Strengthening Cultural Capability and Trauma Informed Care in Women’s Health£175,000

External ID: cf-ocds-b5fd17-1b053612-ac3a-4f54-94e9-20ce45ce8a49 • Added 4 October 2026